ANGLE announces collaboration with Myriad Genetics

AI SummaryClose X

Angle plc announced a collaboration with Myriad Genetics to assess the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic tests. The collaboration involves processing blood samples from cancer patients using ANGLE's Parsortix system to capture intact cancer cells for molecular analysis. Results will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' assay. Further details of the agreement are confidential. Angle's CEO, Andrew Newland, stated the collaboration has the potential to substantially impact patient treatment by improving access to actionable genomic data.

Disclaimer*

UK 100

Latest directors dealings